PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: PIPELINE PART 07: MARKET SEGMENTATION BY ROA Market segmentation by RoA Comparison by RoA Oral - Market size and forecast 2018-2023 Parenteral - Market size and forecast 2018-2023 Market opportunity by RoA PART 08: CUSTOMER LANDSCAPE PART 09: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 10: DECISION FRAMEWORK PART 11: DRIVERS AND CHALLENGES Market drivers Market challenges PART 12: MARKET TRENDS PART 13: VENDOR LANDSCAPE Overview Landscape disruption Competitive scenario PART 14: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors Bayer AG Bristol-Myers Squibb Co. Merck & Co., Inc. Novartis AG Pfizer Inc. PART 15: APPENDIX Research methodology List of abbreviations Definition of market positioning of vendors PART 16: EXPLORE TECHNAVIO   Exhibit 01: Global pharmaceuticals market Exhibit 02: Segments of global pharmaceuticals market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2018 Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 08: Global market: Year-over-year growth 2019-2023 (%) Exhibit 09: Five forces analysis 2018 Exhibit 10: Five forces analysis 2023 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2018 Exhibit 17: Global gastrointestinal stromal tumors therapeutics market pipeline: Overview Exhibit 18: Global gastrointestinal stromal tumors therapeutics market pipeline: Snapshot Exhibit 19: RoA - Market share 2018-2023 (%) Exhibit 20: Comparison by RoA Exhibit 21: Oral - Market size and forecast 2018-2023 ($ millions) Exhibit 22: Oral - Year-over-year growth 2019-2023 (%) Exhibit 23: Parenteral - Market size and forecast 2018-2023 ($ millions) Exhibit 24: Parenteral - Year-over-year growth 2019-2023 (%) Exhibit 25: Market opportunity by RoA Exhibit 26: Customer landscape Exhibit 27: Market share by geography 2018-2023 (%) Exhibit 28: Geographic comparison Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 30: North America - Year-over-year growth 2019-2023 (%) Exhibit 31: Top 3 countries in North America Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 33: Europe - Year-over-year growth 2019-2023 (%) Exhibit 34: Top 3 countries in Europe Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 36: Asia - Year-over-year growth 2019-2023 (%) Exhibit 37: Top 3 countries in Asia Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 39: ROW - Year-over-year growth 2019-2023 (%) Exhibit 40: Top 3 countries in ROW Exhibit 41: Key leading countries Exhibit 42: Market opportunity Exhibit 43: Global rise in geriatric population Exhibit 44: Impact of drivers and challenges Exhibit 45: Vendor landscape Exhibit 46: Landscape disruption Exhibit 47: Vendors covered Exhibit 48: Vendor classification Exhibit 49: Market positioning of vendors Exhibit 50: Bayer AG - Vendor overview Exhibit 51: Bayer AG - Business segments Exhibit 52: Bayer AG - Organizational developments Exhibit 53: Bayer AG - Geographic focus Exhibit 54: Bayer AG - Segment focus Exhibit 55: Bayer AG - Key offerings Exhibit 56: Bayer AG - Key customers Exhibit 57: Bristol-Myers Squibb Co. - Vendor overview Exhibit 58: Bristol-Myers Squibb Co. - Business segments Exhibit 59: Bristol-Myers Squibb Co. - Organizational developments Exhibit 60: Bristol-Myers Squibb Co. - Geographic focus Exhibit 61: Bristol-Myers Squibb Co. - Key offerings Exhibit 62: Bristol-Myers Squibb Co. - Key customers Exhibit 63: Merck & Co. Inc. - Vendor overview Exhibit 64: Merck & Co. Inc. - Business segments Exhibit 65: Merck & Co. Inc. - Organizational developments Exhibit 66: Merck & Co. Inc. - Geographic focus Exhibit 67: Merck & Co. Inc. - Segment focus Exhibit 68: Merck & Co. Inc. - Key offerings Exhibit 69: Merck & Co. Inc. - Key customers Exhibit 70: Novartis AG - Vendor overview Exhibit 71: Novartis AG - Business segments Exhibit 72: Novartis AG - Organizational developments Exhibit 73: Novartis AG - Geographic focus Exhibit 74: Novartis AG - Segment focus Exhibit 75: Novartis AG - Key offerings Exhibit 76: Novartis AG - Key customers Exhibit 77: Pfizer Inc. - Vendor overview Exhibit 78: Pfizer Inc. - Business segments Exhibit 79: Pfizer Inc. - Organizational developments Exhibit 80: Pfizer Inc. - Geographic focus Exhibit 81: Pfizer Inc. - Segment focus Exhibit 82: Pfizer Inc. - Key offerings Exhibit 83: Pfizer Inc. - Key customers Exhibit 84: Validation techniques employed for market sizing Exhibit 85: Definition of market positioning of vendors

Bayer AG Bristol-Myers Squibb Co. Merck & Co., Inc. Novartis AG Pfizer Inc.